264
Participants
Start Date
May 19, 2025
Primary Completion Date
November 30, 2028
Study Completion Date
November 30, 2028
Subthreshold Micropulse Laser (SML)
SML will be applied in line with the DAME Guideline and follow the DAME participant pathway.
Anti-VEGF Monotherapy (standard care)
Anti-VEGFs including ranibizumab and biosimilars, aflibercept, faricimab, and brolucizumab will be used, as per the standard of care at participating sites. The anti-VEGF should be administered in line with the summary of product characteristics (SmPC).
RECRUITING
The Royal Hospitals Belfast, Belfast
NOT_YET_RECRUITING
Birmingham and Midland Eye Centre, Birmingham
NOT_YET_RECRUITING
Sussex Eye Hospital, Brighton
NOT_YET_RECRUITING
Bristol Eye Hospital, Bristol
RECRUITING
Frimley Park Hospital, Camberley
RECRUITING
Gloucestershire Royal Hospital, Gloucester
NOT_YET_RECRUITING
Hull Royal Infirmary, Hull
NOT_YET_RECRUITING
Hinchingbrooke Hospital, Huntingdon
RECRUITING
Royal Liverpool University Hospital, Liverpool
RECRUITING
Central Middlesex Hospital, London
NOT_YET_RECRUITING
Chelsea and Westminster Hospital, London
RECRUITING
Kings College Hospital, London
RECRUITING
Moorfields Eye Hospital, London
RECRUITING
James Cook Hospital, Middlesbrough
NOT_YET_RECRUITING
Royal Gwent Hospital, Newport
NOT_YET_RECRUITING
Queen's Medical Centre, Nottingham
NOT_YET_RECRUITING
East Surrey Hospital, Redhill
NOT_YET_RECRUITING
University Hospital Southampton, Southampton
RECRUITING
Sunderland Eye Hospital, Sunderland
NOT_YET_RECRUITING
Singleton Hospital, Swansea
NOT_YET_RECRUITING
Torbay Hospital, Torquay
RECRUITING
Hillingdon Hospital, Uxbridge
Queen's University, Belfast
OTHER
Belfast Health and Social Care Trust
OTHER